232 related articles for article (PubMed ID: 37237706)
21. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of meropenem in critically ill infant patients.
Yonwises W; Wacharachaisurapol N; Anugulruengkitt S; Maimongkol P; Treyaprasert W
Int J Infect Dis; 2021 Oct; 111():58-64. PubMed ID: 34419581
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
25. Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?
Heffernan AJ; Germano A; Sime FB; Roberts JA; Kimura E
Eur J Clin Pharmacol; 2019 Sep; 75(9):1219-1226. PubMed ID: 31154476
[TBL] [Abstract][Full Text] [Related]
26. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
[TBL] [Abstract][Full Text] [Related]
27. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.
Pea F; Viale P; Furlanut M
Clin Pharmacokinet; 2005; 44(10):1009-34. PubMed ID: 16176116
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
[TBL] [Abstract][Full Text] [Related]
30. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
[TBL] [Abstract][Full Text] [Related]
31. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.
Zhu LL; Zhou Q
Infect Drug Resist; 2018; 11():1105-1117. PubMed ID: 30127628
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.
Fediuk DJ; Sahasrabudhe V; Dawra VK; Zhou S; Sweeney K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1297-1306. PubMed ID: 34213819
[TBL] [Abstract][Full Text] [Related]
34. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
[TBL] [Abstract][Full Text] [Related]
35. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.
Hartman SJF; Brüggemann RJ; Orriëns L; Dia N; Schreuder MF; de Wildt SN
Clin Pharmacokinet; 2020 Feb; 59(2):173-205. PubMed ID: 31432468
[TBL] [Abstract][Full Text] [Related]
37. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support.
Zylbersztajn B; Parker S; Navea D; Izquierdo G; Ortiz P; Torres JP; Fajardo C; Diaz R; Valverde C; Roberts J
Front Pharmacol; 2021; 12():709332. PubMed ID: 34483917
[No Abstract] [Full Text] [Related]
39. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?
Udy AA; Covajes C; Taccone FS; Jacobs F; Vincent JL; Lipman J; Roberts JA
Int J Antimicrob Agents; 2013 Jun; 41(6):564-8. PubMed ID: 23473944
[TBL] [Abstract][Full Text] [Related]
40. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.
Goncalves-Pereira J; Silva NE; Mateus A; Pinho C; Povoa P
BMC Pharmacol Toxicol; 2014 Apr; 15():21. PubMed ID: 24731745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
